These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 19147568)

  • 1. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
    Rounbehler RJ; Li W; Hall MA; Yang C; Fallahi M; Cleveland JL
    Cancer Res; 2009 Jan; 69(2):547-53. PubMed ID: 19147568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.
    Hogarty MD; Norris MD; Davis K; Liu X; Evageliou NF; Hayes CS; Pawel B; Guo R; Zhao H; Sekyere E; Keating J; Thomas W; Cheng NC; Murray J; Smith J; Sutton R; Venn N; London WB; Buxton A; Gilmour SK; Marshall GM; Haber M
    Cancer Res; 2008 Dec; 68(23):9735-45. PubMed ID: 19047152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells.
    Wallick CJ; Gamper I; Thorne M; Feith DJ; Takasaki KY; Wilson SM; Seki JA; Pegg AE; Byus CV; Bachmann AS
    Oncogene; 2005 Aug; 24(36):5606-18. PubMed ID: 16007177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.
    Koomoa DL; Geerts D; Lange I; Koster J; Pegg AE; Feith DJ; Bachmann AS
    Int J Oncol; 2013 Apr; 42(4):1219-28. PubMed ID: 23440295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.
    Samal K; Zhao P; Kendzicky A; Yco LP; McClung H; Gerner E; Burns M; Bachmann AS; Sholler G
    Int J Cancer; 2013 Sep; 133(6):1323-33. PubMed ID: 23457004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.
    Nilsson JA; Keller UB; Baudino TA; Yang C; Norton S; Old JA; Nilsson LM; Neale G; Kramer DL; Porter CW; Cleveland JL
    Cancer Cell; 2005 May; 7(5):433-44. PubMed ID: 15894264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
    Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
    Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
    Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
    Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma.
    Koomoa DL; Yco LP; Borsics T; Wallick CJ; Bachmann AS
    Cancer Res; 2008 Dec; 68(23):9825-31. PubMed ID: 19047162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.
    Dolman ME; Poon E; Ebus ME; den Hartog IJ; van Noesel CJ; Jamin Y; Hallsworth A; Robinson SP; Petrie K; Sparidans RW; Kok RJ; Versteeg R; Caron HN; Chesler L; Molenaar JJ
    Clin Cancer Res; 2015 Nov; 21(22):5100-9. PubMed ID: 26202950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic drug combination GC7/DFMO suppresses hypusine/spermidine-dependent eIF5A activation and induces apoptotic cell death in neuroblastoma.
    Schultz CR; Geerts D; Mooney M; El-Khawaja R; Koster J; Bachmann AS
    Biochem J; 2018 Jan; 475(2):531-545. PubMed ID: 29295892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
    Saulnier Sholler GL; Gerner EW; Bergendahl G; MacArthur RB; VanderWerff A; Ashikaga T; Bond JP; Ferguson W; Roberts W; Wada RK; Eslin D; Kraveka JM; Kaplan J; Mitchell D; Parikh NS; Neville K; Sender L; Higgins T; Kawakita M; Hiramatsu K; Moriya SS; Bachmann AS
    PLoS One; 2015; 10(5):e0127246. PubMed ID: 26018967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.
    Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F
    Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling.
    Mohammed A; Janakiram NB; Madka V; Ritchie RL; Brewer M; Biddick L; Patlolla JM; Sadeghi M; Lightfoot S; Steele VE; Rao CV
    Cancer Prev Res (Phila); 2014 Dec; 7(12):1198-209. PubMed ID: 25248858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine.
    Qu N; Ignatenko NA; Yamauchi P; Stringer DE; Levenson C; Shannon P; Perrin S; Gerner EW
    Biochem J; 2003 Oct; 375(Pt 2):465-70. PubMed ID: 12859253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyamine synthesis as a target of
    Bachmann AS; Geerts D
    J Biol Chem; 2018 Nov; 293(48):18757-18769. PubMed ID: 30404920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MYCN oncoprotein as a drug development target.
    Lu X; Pearson A; Lunec J
    Cancer Lett; 2003 Jul; 197(1-2):125-30. PubMed ID: 12880971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma.
    Bassiri H; Benavides A; Haber M; Gilmour SK; Norris MD; Hogarty MD
    Transl Pediatr; 2015 Jul; 4(3):226-38. PubMed ID: 26835380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.
    Evageliou NF; Haber M; Vu A; Laetsch TW; Murray J; Gamble LD; Cheng NC; Liu K; Reese M; Corrigan KA; Ziegler DS; Webber H; Hayes CS; Pawel B; Marshall GM; Zhao H; Gilmour SK; Norris MD; Hogarty MD
    Clin Cancer Res; 2016 Sep; 22(17):4391-404. PubMed ID: 27012811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.